FIELD: medicine.
SUBSTANCE: invention relates to medicine and to a method for diagnosing bronchial obstruction in a lung transplant recipient, where the concentration of galectin-3 and the level of expression of microRNA-339 are determined in the venous blood plasma of the recipient of the lung transplant, and when the concentration of galectin-3 is more than 11.7 ng/ml and the level expression of microRNA-339 more than 0.02 diagnose the presence of obstruction of the bronchus of a pulmonary transplant.
EFFECT: invention ensures availability and non-invasiveness of diagnostics, shortening the time of its implementation, while at the same time achieving reliable diagnostics of obstructive changes in the bronchi after lung transplantation.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSING BRONCHIAL OBSTRUCTION IN LUNG TRANSPLANT RECIPIENT | 2020 |
|
RU2760195C1 |
| METHOD FOR DIAGNOSING BRONCHIAL OBSTRUCTION IN LUNG TRANSPLANT RECIPIENT | 2020 |
|
RU2759048C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS IN TRANSPLANTED HEART | 2021 |
|
RU2758993C1 |
| METHOD FOR DIAGNOSING BACTEREMIA ASSOCIATED WITH GRAM-NEGATIVE MICROORGANISMS IN HEART OR LUNG RECIPIENTS | 2021 |
|
RU2780280C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS IN DONOR HEART RECIPIENTS | 2021 |
|
RU2761470C1 |
| METHOD FOR PREOPERATIVE PREDICTION OF ACUTE CELLULAR REJECTION OF A TRANSPLANTED HEART | 2022 |
|
RU2798948C1 |
| METHOD FOR DIAGNOSING ACUTE TRANSPLANT REJECTION IN TRANSPLANTED HEART RECIPIENTS | 2020 |
|
RU2758994C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS IN CARDIAC TRANSPLANT RECIPIENTS | 2021 |
|
RU2760093C1 |
| METHOD FOR DIAGNOSING ACUTE REJECTION OF TRANSPLANT IN TRANSPLANTED HEART RECIPIENT | 2020 |
|
RU2758973C1 |
| METHOD FOR NON-INVASIVE DIAGNOSIS OF MYOCARDIAL FIBROSIS OF TRANSPLANTED HEART AT A LONG POST-TRANSPLANTATION PERIOD IN RECIPIENTS SUFFERING ACUTE REJECTION | 2019 |
|
RU2709193C1 |
